Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best S&P 500 stocks with huge upside potential. On June 24, ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

Regeneron and GlaxoSmithKline have joined forces to generate genetic sequence data from the 500,000 volunteers in the UK’s Biobank database. The companies hope the initiative will give insights ...

Celltrion UK has officially opened its new UK headquarters at the Charter Building in Uxbridge, UK, reinforcing the company’s ...

Lynozyfic’s global sales are projected to reach $707 million by 2031.

TARRYTOWN, N.Y. - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a prominent biotechnology company with annual revenue of $14.1 billion and strong financial health according to InvestingPro analysis, ...

Regeneron (NASDAQ: REGN) Pharmaceuticals, a leading biotechnology company with a market capitalization of $55.92 billion, has been navigating a challenging landscape in recent months.The company’s ...

UK regulators on Tuesday fined 23andMe 2.31 million pounds ($3.1 million) for data privacy violations stemming from the ...

The fine comes as the DNA testing firm, which filed for bankruptcy in March, is set to be sold to a new owner.

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) ...

A cyber attack on the genetic testing firm saw personal information of 155,592 UK residents accessed in a major cyber attack ...